{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:29:09Z","timestamp":1787178549044,"version":"build-2736575974"},"reference-count":41,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR132948"],"award-info":[{"award-number":["NIHR132948"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>\nDiabetic retinopathy is a major cause of sight loss in people with diabetes, with a high risk of macular oedema, vitreous haemorrhage or other complications. Panretinal photocoagulation is the primary treatment for proliferative retinopathy. Anti-vascular endothelial growth factor drugs are used to treat various eye conditions and may be beneficial for people with proliferative or non-proliferative retinopathy.<\/jats:p>\n<\/jats:sec>\nMethods<\/jats:title>\nThe Anti-VEGF In Diabetes project sought to investigate the clinical and cost-effectiveness of using anti-vascular endothelial growth factor to prevent retinopathy progression when compared to panretinal photocoagulation or no treatment. A systematic review with network meta-analysis of randomised controlled trials of anti-vascular endothelial growth factor (alone or in combination with panretinal photocoagulation) to treat retinopathy was conducted. The database searches were updated in May 2023. Individual participant data from larger trials were sought. A systematic review of non-randomised studies was performed.<\/jats:p>\nExisting cost-effectiveness analyses were reviewed, and a new economic model was developed, informed by the individual participant data meta-analysis. The model also estimated the value of undertaking further research to resolve decision uncertainty.<\/jats:p>\n<\/jats:sec>\nResults<\/jats:title>\nThe review found that anti-vascular endothelial growth factors produced a slight, and not clinically meaningful, benefit over panretinal photocoagulation in best corrected visual acuity, after 1 year of follow-up in people with proliferative retinopathy (mean difference of 4.5 ETDRS letters; 95% credible interval \u22120.7 to 8.2). There was no evidence of a difference in effectiveness among the different anti-vascular endothelial growth factors. The benefit of anti-vascular endothelial growth factor appears to decline over time. Anti-vascular endothelial growth factor therapy may be more effective in people with poorer initial visual acuity. Anti-vascular endothelial growth factor had no impact on vision in people with non-proliferative retinopathy. Anti-vascular endothelial growth factor reduces rates of macular oedema and vitreous haemorrhage and may slow down the progression of retinopathy.<\/jats:p>\nAnti-vascular endothelial growth factors were predicted to be more costly but similarly effective to panretinal photocoagulation, with a net health benefit of \u22120.214 quality-adjusted life-years at a \u00a320,000 willingness-to-pay threshold. Only under very select conditions might anti-vascular endothelial growth factors have the potential for cost-effectiveness to treat proliferative retinopathy. There is potentially significant value in reducing uncertainty through further primary research.<\/jats:p>\n<\/jats:sec>\nConclusions<\/jats:title>\nAnti-vascular endothelial growth factor has no clinically meaningful benefit over panretinal photocoagulation for preserving visual acuity, but it may delay or prevent progression to macular oedema and vitreous haemorrhage. The long-term effectiveness and safety of anti-vascular endothelial growth factor treatment are unclear, particularly as additional panretinal photocoagulation and anti-vascular endothelial growth factor treatment will be required over time.<\/jats:p>\nAnti-vascular endothelial growth factors are therefore unlikely to be a cost-effective treatment for early proliferative retinopathy compared to panretinal photocoagulation. They are generally associated with higher costs and similar health outcomes across various scenarios. The long-term cost-effectiveness of anti-vascular endothelial growth factor is uncertain due to the lack of long-term clinical evidence.<\/jats:p>\n<\/jats:sec>\nFuture work<\/jats:title>\nFurther, robust studies with more than 2 years follow-up are required to evaluate the long-term efficacy and safety of anti-vascular endothelial growth factor use, and the effect of additional anti-vascular endothelial growth factor and panretinal photocoagulation therapy over time. Clinical trials or observational studies focusing on the use of anti-vascular endothelial growth factor in people with poorer vision at time of treatment may also be useful.<\/jats:p>\n<\/jats:sec>\nFunding<\/jats:title>\nThis synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number NIHR132948.<\/jats:p>\n<\/jats:sec>","DOI":"10.3310\/krwp1264","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T14:49:09Z","timestamp":1746888549000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and economic analysis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1999-8515","authenticated-orcid":true,"given":"Mark","family":"Simmonds","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-3689","authenticated-orcid":true,"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Rob","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4569-5136","authenticated-orcid":true,"given":"Alexis","family":"Llewellyn","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2765-7363","authenticated-orcid":true,"given":"Ruth","family":"Walker","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-1099","authenticated-orcid":true,"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-9109","authenticated-orcid":true,"given":"Laura","family":"Bojke","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-4724","authenticated-orcid":true,"given":"Lesley","family":"Stewart","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rush","sequence":"additional","affiliation":[{"name":"Patient representative, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2031-6390","authenticated-orcid":true,"given":"John","family":"Lawrenson","sequence":"additional","affiliation":[{"name":"Department of Optometry and Visual Sciences, City, University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6265-0381","authenticated-orcid":true,"given":"Tunde","family":"Peto","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-3089","authenticated-orcid":true,"given":"David","family":"Steel","sequence":"additional","affiliation":[{"name":"Biosciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"key2025061621565300_ref1-bib1","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"key2025061621565300_ref2-bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/archopht.1979.01020010310003","article-title":"Four risk factors for severe visual loss in diabetic retinopathy. The third report from the diabetic retinopathy study. The diabetic retinopathy study research group","volume":"97","author":"The Diabetic Retinopathy Study Research Group","year":"1979","journal-title":"Arch Ophthalmol"},{"key":"key2025061621565300_ref3-bib3","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1097\/IAE.0000000000000192","article-title":"Ocular findings at initial pan retinal photocoagulation for proliferative diabetic retinopathy predict the need for future pars plana vitrectomy","volume":"34","author":"Parikh","year":"2014","journal-title":"Retina"},{"key":"key2025061621565300_ref4-bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabet Med"},{"key":"key2025061621565300_ref5-bib5","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","article-title":"Early photocoagulation for diabetic retinopathy: ETDRS report number 9","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref6-bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19510","article-title":"Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation","volume":"19","author":"Royle","year":"2015","journal-title":"Health Technol Assess"},{"key":"key2025061621565300_ref7-bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref8-bib8","volume-title":"Ranibizumab for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2013"},{"key":"key2025061621565300_ref9-bib9","volume-title":"Aflibercept for Treating Diabetic Macular Oedema","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"key2025061621565300_ref10-bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the panorama randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"key2025061621565300_ref11-bib11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref12-bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2019.03.005","article-title":"Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions","volume":"204","author":"Wubben","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"key2025061621565300_ref13-bib13","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ophtha.2018.04.007","article-title":"Guidelines on diabetic eye care: The International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings","volume":"125","author":"Wong","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref14-bib14","volume-title":"Diabetic Retinopathy (Guidance in Development)","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"key2025061621565300_ref15-bib15","doi-asserted-by":"crossref","DOI":"10.3310\/PCGV5709","article-title":"Anti-VEGF drugs compared with laser photocoagulation for the treatment of diabetic retinopathy: a systematic review and meta-analysis","author":"Simmonds","year":"2024","journal-title":"Health Technol Assess"},{"key":"key2025061621565300_ref16-bib16","article-title":"Anti-VEGF drugs compared with laser photocoagulation for the treatment of proliferative diabetic retinopathy: a systematic review and IPD meta-analysis","author":"Simmonds","year":"2025","journal-title":"Health Technol Assess"},{"key":"key2025061621565300_ref17-bib17","doi-asserted-by":"crossref","DOI":"10.3310\/NHYK3694","article-title":"A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy","author":"Hodgson","year":"2025","journal-title":"Health Technol Assess"},{"key":"key2025061621565300_ref18-bib18","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.jval.2024.03.007","article-title":"Anti-vascular endothelial growth factor drugs compared with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy: a cost-effectiveness analysis","volume":"27","author":"Walton","year":"2024","journal-title":"Value Health"},{"key":"key2025061621565300_ref19-bib19","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"Centre for Reviews and Dissemination","year":"n.d"},{"key":"key2025061621565300_ref20-bib20","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"key2025061621565300_ref21-bib21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2025061621565300_ref22-bib22","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (clarity): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"key2025061621565300_ref23-bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"key2025061621565300_ref24-bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ophtha.2017.12.008","article-title":"Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study)","volume":"125","author":"Figueira","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref25-bib25","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1111\/aos.14312","article-title":"Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy \u2013 the PRIDE study","volume":"98","author":"Lang","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"key2025061621565300_ref26-bib26","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaophthalmol.2021.0606","article-title":"Effect of intravitreous anti-vascular endothelial growth factor vs sham treatment for prevention of vision-threatening complications of diabetic retinopathy: the protocol w randomized clinical trial","volume":"139","author":"Maturi","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"key2025061621565300_ref27-bib27","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/rssa.12579","article-title":"Multilevel network meta-regression for population-adjusted treatment comparisons","volume":"183","author":"Phillippo","year":"2020","journal-title":"J R Stat Soc Ser A Stat Soc"},{"key":"key2025061621565300_ref28-bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.29271\/jcpsp.2018.12.923","article-title":"Panretinal photocoagulation plus intravitreal bevacizumab versus panretinal photocoagulation alone for proliferative diabetic retinopathy","volume":"28","author":"Ali","year":"2018","journal-title":"J Coll Physicians Surg Pak"},{"key":"key2025061621565300_ref29-bib29","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/IAE.0000000000000363","article-title":"A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy","volume":"5","author":"Ferraz","year":"2015","journal-title":"Retina"},{"key":"key2025061621565300_ref30-bib30","first-page":"268","article-title":"Panretinal photocoagulation versus intravitreal bevacizumab for proliferative diabetic retinopathy treatment","volume":"7","author":"Marashi","year":"2017","journal-title":"Adv Ophthalmol Vis Sys"},{"key":"key2025061621565300_ref31-bib31","first-page":"157","article-title":"Comparison of efficacy of combination therapy of an intravitreal injection of bevacizumab and photocoagulation versus pan retinal photocoagulation alone in high risk proliferative diabetic retinopathy","volume":"37","author":"Rebecca","year":"2021","journal-title":"Pak J Med Sci"},{"key":"key2025061621565300_ref32-bib32","first-page":"526","article-title":"ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy","volume":"83","author":"Barroso","year":"2020","journal-title":"Arq Bras Oftalmol"},{"key":"key2025061621565300_ref33-bib33","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"key2025061621565300_ref34-bib34","first-page":"10","article-title":"Comparison between panretinal photocoagulation and panretinal photocoagulation plus intravitreal bevacizumab in proliferative diabetic retinopathy","volume":"24","author":"Ahmad","year":"2012","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"key2025061621565300_ref35-bib35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/jovr.jovr_160_17","article-title":"The effect of panretinal photocoagulation (PRP) versus intravitreal bevacizumab (IVB) plus PRP on peripapillary retinal nerve fiber layer (RNFL) thickness analyzed by optical coherence tomography in patients with proliferative diabetic retinopathy","volume":"14","author":"Roohipour","year":"2019","journal-title":"J Ophthalmic Vis Res"},{"key":"key2025061621565300_ref36-bib36","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.1111\/aos.14907","article-title":"Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy \u2013 the non-interventional second year follow-up to the PRIDE study","volume":"100","author":"Lang","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"key2025061621565300_ref37-bib37","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/bjophthalmol-2016-308400","article-title":"Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy","volume":"100","author":"Bandello","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"key2025061621565300_ref38-bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme05050","article-title":"Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT","volume":"5","author":"Sivaprasad","year":"2018","journal-title":"Eff Mech Eval"},{"key":"key2025061621565300_ref39-bib39","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.ophtha.2016.05.037","article-title":"Cost evaluation of panretinal photocoagulation versus intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"123","author":"Lin","year":"2016","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref40-bib40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2018.02.038","article-title":"Cost evaluation of early vitrectomy versus panretinal photocoagulation and intravitreal ranibizumab for proliferative diabetic retinopathy","volume":"125","author":"Lin","year":"2018","journal-title":"Ophthalmology"},{"key":"key2025061621565300_ref41-bib41","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1167\/iovs.02-1100","article-title":"How sensitive to clinical change are ETDRS logMAR visual acuity measurements?","volume":"44","author":"Rosser","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/KRWP1264\/KRWP1264.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2047825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T06:42:29Z","timestamp":1750142549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/published-articles\/KRWP1264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":41,"alternative-id":["10.3310\/KRWP1264"],"URL":"https:\/\/doi.org\/10.3310\/krwp1264","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"08-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"01-2024","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"01-2025","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}